WO2011071541A3 - Cadherin modulatory agents - Google Patents

Cadherin modulatory agents Download PDF

Info

Publication number
WO2011071541A3
WO2011071541A3 PCT/US2010/003155 US2010003155W WO2011071541A3 WO 2011071541 A3 WO2011071541 A3 WO 2011071541A3 US 2010003155 W US2010003155 W US 2010003155W WO 2011071541 A3 WO2011071541 A3 WO 2011071541A3
Authority
WO
WIPO (PCT)
Prior art keywords
cadherin
modulatory agents
compositions
agents
activities
Prior art date
Application number
PCT/US2010/003155
Other languages
French (fr)
Other versions
WO2011071541A2 (en
Inventor
Xiang-Lei Yang
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of WO2011071541A2 publication Critical patent/WO2011071541A2/en
Publication of WO2011071541A3 publication Critical patent/WO2011071541A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions are provided comprising agents such as small molecules that modulate the biological activity of cadherins, the angiostatic activity of tryptophanyl-tRNA synthetases (WRS), or both. Also provided are methods of using such compositions for modulating cadherin-mediated activities, such as angiogenesis, and for treating conditions associated with these activities.
PCT/US2010/003155 2009-12-11 2010-12-13 Cadherin modulatory agents WO2011071541A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28403509P 2009-12-11 2009-12-11
US61/284,035 2009-12-11

Publications (2)

Publication Number Publication Date
WO2011071541A2 WO2011071541A2 (en) 2011-06-16
WO2011071541A3 true WO2011071541A3 (en) 2011-12-29

Family

ID=44146100

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/003155 WO2011071541A2 (en) 2009-12-11 2010-12-13 Cadherin modulatory agents

Country Status (1)

Country Link
WO (1) WO2011071541A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
BR112016030740A2 (en) 2014-07-01 2018-02-20 Pfizer Inc. bispecific heterodimeric bodies and their uses
DK3283524T3 (en) 2015-04-17 2023-05-30 Amgen Res Munich Gmbh BISPECIFIC ANTIBODY CONSTRUCTIONS AGAINST CDH3 and CD3
WO2023211934A1 (en) * 2022-04-25 2023-11-02 The Regents Of The University Of Michigan Lipids, formulations, and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0032708B1 (en) * 1980-01-18 1983-05-04 Tanabe Seiyaku Co., Ltd. Tryptophan derivative, process for preparing same and a pharmaceutical composition containing such derivative
US20080311121A1 (en) * 2000-03-31 2008-12-18 Imclone Systems Inc. Antibody antagonists of ve-cadherin without adverse effects on vascular permeability

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0032708B1 (en) * 1980-01-18 1983-05-04 Tanabe Seiyaku Co., Ltd. Tryptophan derivative, process for preparing same and a pharmaceutical composition containing such derivative
US20080311121A1 (en) * 2000-03-31 2008-12-18 Imclone Systems Inc. Antibody antagonists of ve-cadherin without adverse effects on vascular permeability

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIBERT ET AL.: "Establishment of cell-cell junctions depends on the oligomeric states of VE- cadherin.", J BIOCHEM., vol. 143, no. 6, 2008, pages 821 - 832 *
HEWAT ET AL.: "Architecture of the VE-cadherin hexamer.", J MOL BIOL., vol. 365, no. 3, 2007, pages 744 - 751, XP005733366, DOI: doi:10.1016/j.jmb.2006.10.052 *
SHEN ET AL.: "Catalytic mechanism of the tryptophan activation reaction revealed by crystal structures of human tryptophanyl-tRNA synthetase in different enzymatic states.", NUCLEIC ACIDS RES., vol. 36, no. 4, 2008, pages 1288 - 1299 *
TZIMA ET AL.: "VE-cadherin Links tRNA Synthetase Cytokine to Anti-angiogenic Function.", J BIOL CHEM., vol. 280, no. 4, 2005, pages 2405 - 2408 *
VESTWEBER.: "VE-Cadherin: The Major Endothelial Adhesion Molecule Controlling Cellular Junctions and Blood Vessel Formation.", ARTERIOSCLER THROMB VASC BIOL., vol. 28, no. 2, 2008, pages 223 - 232 *
ZHOU ET AL.: "Orthogonal use of a human tRNA synthetase active site to achieve multifunctionality.", NAT STRUCT MOL BIOL., vol. 17, no. 1, 13 December 2009 (2009-12-13), pages 57 - 61, XP009145388 *

Also Published As

Publication number Publication date
WO2011071541A2 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
PH12020550450A1 (en) Certain chemical entities, compositions and methods
WO2011140202A3 (en) Mif modulators
BR112018013111A2 (en) non-aqueous inoculant composition, coated plant propagation material, kit, plant, plant part, processed product, culture, and method.
WO2010021693A3 (en) Mif modulators
WO2011139489A3 (en) Compounds that modulate intracellular calcium
WO2009156484A3 (en) Organic compounds
IN2014MN00989A (en)
WO2013075083A8 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
WO2012068589A3 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013075084A8 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MY172156A (en) Modulators of methyl modifying enzymes, compositions and uses thereof
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (en) Compounds and compositions as modulators of gpr119 activity
UA116093C2 (en) Methods and compositions for weed control
MA33894B1 (en) The operation of the treatment of perfridone
WO2012170931A3 (en) Compounds that modulate intracellular calcium
WO2009089494A3 (en) Pharmaceutical compositions
WO2012027710A3 (en) Compounds that modulate intracellular calcium
WO2007101864A3 (en) Compounds that modulate ppar activity, their preparation and use
MX2012004078A (en) Compounds and compositions as modulators of gpr119 activity.
WO2011114232A3 (en) Herbicide-tolerant plants
WO2011139765A3 (en) Compounds that modulate intracellular calcium
WO2011034962A3 (en) Compounds that modulate intracellular calcium
WO2012170951A3 (en) Compounds that modulate intracellular calcium
WO2013177492A3 (en) Novel lipase inhibitors, reporter substrates and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10836325

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10836325

Country of ref document: EP

Kind code of ref document: A2